云南白药(000538) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 was approximately ¥9.40 billion, a decrease of 0.66% compared to the same period last year[8] - Net profit attributable to shareholders was approximately ¥1.14 billion, reflecting a 0.55% increase year-over-year[8] - The net profit after deducting non-recurring gains and losses was approximately ¥1.09 billion, down 3.61% from the previous year[8] - The basic earnings per share for the period was ¥0.64, up 1.59% year-over-year[8] - Industrial revenue for the first three quarters reached ¥11.58 billion, an increase of ¥906 million, with a year-on-year growth rate of 8.48%[8] - Total revenue for the current period reached ¥30,654,214,209.01, an increase of 2.46% compared to ¥29,915,155,069.84 in the previous period[28] - Net profit for the current period was ¥4,789,170,075.42, representing a growth of 10.65% from ¥4,329,700,490.03 in the previous period[29] - Total comprehensive income attributable to the parent company reached CNY 4,778,908,089.57, an increase from CNY 4,321,812,111.74 in the previous period, reflecting a growth of approximately 10.6%[30] - Basic and diluted earnings per share increased to CNY 2.68, up from CNY 2.42, representing a growth of 10.7%[30] Assets and Liabilities - The company's total assets at the end of the reporting period were approximately ¥53.34 billion, an increase of 0.81% from the end of the previous year[8] - The company's total assets increased to ¥53,343,484,721.39, compared to ¥52,914,181,333.05, marking a growth of 0.81%[25] - Total liabilities decreased to ¥13,525,611,110.78 from ¥14,048,096,770.78, a reduction of 3.70%[26] - The total equity attributable to shareholders rose to ¥39,733,402,690.02, up from ¥38,831,946,424.51, indicating an increase of 2.31%[26] Cash Flow - The net cash flow from operating activities for the year-to-date was approximately ¥4.46 billion, reflecting a 9.40% increase compared to the previous year[8] - Cash inflow from operating activities totaled CNY 34,692,435,604.90, compared to CNY 32,872,412,099.37 in the previous period, marking an increase of about 5.5%[31] - Net cash flow from operating activities was CNY 4,455,969,511.54, up from CNY 4,073,138,745.34, indicating a growth of approximately 9.4%[32] - Cash outflow from investing activities amounted to CNY 7,082,314,175.11, compared to CNY 6,283,661,079.58 in the previous period, reflecting an increase of about 12.7%[32] - Net cash flow from investing activities was negative at CNY -2,213,387,280.77, worsening from CNY -1,157,794,613.21 in the previous period[32] - Cash flow from financing activities resulted in a net outflow of CNY -4,470,094,047.29, compared to CNY -3,661,695,477.51 in the previous period, indicating a decline of approximately 22.1%[34] - The ending balance of cash and cash equivalents was CNY 8,041,658,446.84, down from CNY 13,402,807,258.02 in the previous period, a decrease of about 40.0%[34] Shareholder Information - The total number of common shareholders at the end of the reporting period is 166,806[16] - The top 10 shareholders hold a combined 66.09% of the shares, with Yunnan State-Owned Equity Operation Management Co., Ltd. holding 26.20% and Xinhua Group holding 21.28%[16] - The company has no preferred shareholders as of the reporting period[18] Investments and Acquisitions - The company reported a significant increase of 75.47% in trading financial assets, totaling approximately ¥4.47 billion, due to investments in high-security, liquid financial products[13] - The company’s investment income increased by 38.83% to approximately ¥951 million, primarily from investments in Shanghai Pharmaceuticals[15] - The acquisition of An Guo Shi Ju Yao Tang Pharmaceutical Co., Ltd. was completed for a total consideration of 660 million CNY, enhancing the company's market presence and product offerings[19] - The non-public issuance of exchangeable bonds was completed with a total scale of 2 billion CNY on October 22, 2025[22] Operational Efficiency and Future Plans - The company aims to expand its market presence and enhance operational efficiency through strategic acquisitions and partnerships[20] - The company plans to expand its market presence and invest in new technologies to drive future growth[27] Research and Development - Research and development expenses for the current period were ¥234,998,200.97, compared to ¥216,182,636.47, reflecting an increase of 8.67%[28]